{
    "componentChunkName": "component---src-templates-docs-js",
    "path": "/periprocedureel-beleid/overzicht-trombo-embolie-risico",
    "result": {"data":{"site":{"siteMetadata":{"title":"LTA Antistollingszorg"}},"mdx":{"fields":{"id":"664917d9-6333-5061-b704-198f1e1f97f6","title":"Overzicht trombo-embolie risico","slug":"/periprocedureel-beleid/overzicht-trombo-embolie-risico"},"body":"var _excluded = [\"components\"];\n\nfunction _extends() { _extends = Object.assign ? Object.assign.bind() : function (target) { for (var i = 1; i < arguments.length; i++) { var source = arguments[i]; for (var key in source) { if (Object.prototype.hasOwnProperty.call(source, key)) { target[key] = source[key]; } } } return target; }; return _extends.apply(this, arguments); }\n\nfunction _objectWithoutProperties(source, excluded) { if (source == null) return {}; var target = _objectWithoutPropertiesLoose(source, excluded); var key, i; if (Object.getOwnPropertySymbols) { var sourceSymbolKeys = Object.getOwnPropertySymbols(source); for (i = 0; i < sourceSymbolKeys.length; i++) { key = sourceSymbolKeys[i]; if (excluded.indexOf(key) >= 0) continue; if (!Object.prototype.propertyIsEnumerable.call(source, key)) continue; target[key] = source[key]; } } return target; }\n\nfunction _objectWithoutPropertiesLoose(source, excluded) { if (source == null) return {}; var target = {}; var sourceKeys = Object.keys(source); var key, i; for (i = 0; i < sourceKeys.length; i++) { key = sourceKeys[i]; if (excluded.indexOf(key) >= 0) continue; target[key] = source[key]; } return target; }\n\n/* @jsxRuntime classic */\n\n/* @jsx mdx */\nvar Risicofactoren = function Risicofactoren() {\n  return mdx(List, {\n    size: \"small\",\n    bordered: true,\n    mdxType: \"List\"\n  }, mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Atriumfibrilleren\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Linker ventrikel ejectiefractie < 35%\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Voorgeschiedenis van een doorgemaakte trombo-embolie (cerebro vasculair accident, transient ischemic attack, of arteri\\xEBle embolie)\"));\n};\n\nvar _frontmatter = {\n  \"title\": \"Overzicht trombo-embolie risico\",\n  \"metaTitle\": \"Overzicht trombo-embolie risico\",\n  \"metaDescription\": \"Een overzicht van het trombo-embolie risico. Het risico op trombo-embolieën is afhankelijk van de indivatie, de duur van de onderbreking en de wijze van antistolling.\",\n  \"date\": \"26-07-2023\",\n  \"parent\": \"Periprocedureel Beleid\",\n  \"type\": \"\",\n  \"nextUrl\": \"/periprocedureel-beleid/overzicht-periprocedureel-bloedingsrisico\",\n  \"nextText\": \"Overzicht periprocedureel bloedingsrisico\",\n  \"previousUrl\": \"/periprocedureel-beleid/algemene-informatie\",\n  \"previousText\": \"Periprocedureel beleid\"\n};\n\nvar makeShortcode = function makeShortcode(name) {\n  return function MDXDefaultShortcode(props) {\n    console.warn(\"Component \" + name + \" was not imported, exported, or provided by MDXProvider as global scope\");\n    return mdx(\"div\", props);\n  };\n};\n\nvar ListItem = makeShortcode(\"ListItem\");\nvar layoutProps = {\n  Risicofactoren: Risicofactoren,\n  _frontmatter: _frontmatter\n};\nvar MDXLayout = \"wrapper\";\nreturn function MDXContent(_ref) {\n  var components = _ref.components,\n      props = _objectWithoutProperties(_ref, _excluded);\n\n  return mdx(MDXLayout, _extends({}, layoutProps, props, {\n    components: components,\n    mdxType: \"MDXLayout\"\n  }), mdx(\"p\", null, \"Het risico op trombo-embolie\\xEBn is afhankelijk van:\"), mdx(\"ul\", null, mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"De indicatie waarvoor de anticoagulantia worden gegeven\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"De duur van de onderbreking van antistolling\"), mdx(\"li\", {\n    parentName: \"ul\"\n  }, \"De wijze van antistolling\")), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(\"h2\", null, \"Hoog risico\"), mdx(List, {\n    bordered: true,\n    mdxType: \"List\"\n  }, mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, mdx(Statistic, {\n    valueStyle: {\n      color: '#cf1322'\n    },\n    title: \"Hoog risico voor arteri\\xEBle trombo-embolie\",\n    value: '> 10% per jaar',\n    mdxType: \"Statistic\"\n  })), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, mdx(Statistic, {\n    valueStyle: {\n      color: '#cf1322'\n    },\n    title: \"Hoog risico voor veneuze trombo-embolie\",\n    value: '> 10% per maand',\n    mdxType: \"Statistic\"\n  }))), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(\"h3\", null, \"Klinische status hoog risico\"), mdx(List, {\n    bordered: true,\n    mdxType: \"List\"\n  }, mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Ge\\xEFsoleerd atriumfibrilleren, zonder klepgebrek, met CHA\", mdx(\"sup\", null, \"2\"), \"DS\", mdx(\"sup\", null, \"2\"), \"-VASc-score: \", mdx(\"b\", null, \"8-9\")), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Ge\\xEFsoleerd atriumfibrilleren met reumatische hartziekte\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Atriumfibrilleren met mechanische hartklep of recent (<6 maanden) herseninfarct/TIA ongeacht de CHA\", mdx(\"sup\", null, \"2\"), \"DS\", mdx(\"sup\", null, \"2\"), \"-VASc-score\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Bij biokleppen (inclusief TAVI) < 3 maanden geleden geplaatst, alleen  alleen op indicatie van de operateur\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Mechanische hartklep in mitralis, tricuspidalis of pulmonalis positie\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Aortamechanoprothesen met extra\", \" \", mdx(Popover, {\n    content: mdx(Risicofactoren, {\n      mdxType: \"Risicofactoren\"\n    }),\n    title: \"Risicofactoren\",\n    mdxType: \"Popover\"\n  }, mdx(\"a\", {\n    href: \"#\"\n  }, \"risicofactor\")), \" \", \"in overleg met de operateur\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Hartklepprothese (inclusief\", \" \", mdx(Popover, {\n    content: \"De eerste drie maanden na chirurgie een bioklep beschouwen als zijnde ‘mechanoprothese’.\",\n    title: \"Bioklep\",\n    mdxType: \"Popover\"\n  }, mdx(\"a\", {\n    href: \"#\"\n  }, \"bioklep\")), \") met extra\", \" \", mdx(Popover, {\n    content: mdx(Risicofactoren, {\n      mdxType: \"Risicofactoren\"\n    }),\n    title: \"Risicofactoren\",\n    mdxType: \"Popover\"\n  }, mdx(\"a\", {\n    href: \"#\"\n  }, \"risicofactor\"))), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Mechanische hartklep oud model: caged ball, tilting disc (Starr-Edwards, Bj\\xF6rk-Shiley)\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Intracardiale trombus\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"< 3 maanden na een veneuze trombo-embolie (VTE) (eerste episode of recidief)\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Recidief VTE onder antistolling\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Recidief VTE bij eerdere tijdelijke onderbreking van antistolling (ook > 3 maanden laatste event)\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Recidiverend herseninfarct/ TIA bij symptomatische ACI stenose\")), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(\"h2\", null, \"Laag risico\"), mdx(List, {\n    bordered: true,\n    mdxType: \"List\"\n  }, mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, mdx(Statistic, {\n    valueStyle: {\n      color: '#3f8600'\n    },\n    title: \"Laag risico voor arteri\\xEBle trombo-embolie\",\n    value: '< 10% per jaar',\n    mdxType: \"Statistic\"\n  })), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, mdx(Statistic, {\n    valueStyle: {\n      color: '#3f8600'\n    },\n    title: \"Laag risico voor veneuze trombo-embolie\",\n    value: '< 10% per maand',\n    mdxType: \"Statistic\"\n  }))), mdx(Divider, {\n    mdxType: \"Divider\"\n  }), mdx(\"h3\", null, \"Klinische status laag risico\"), mdx(List, {\n    bordered: true,\n    mdxType: \"List\"\n  }, mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Ge\\xEFsoleerd atriumfibrilleren, CHA\", mdx(\"sup\", null, \"2\"), \"DS\", mdx(\"sup\", null, \"2\"), \"-VASc-score: \", mdx(\"b\", null, \"0-7\"), \" en geen recent (< 6 maanden) herseninfarct/ TIA\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Mechanische hartklep in aortapositie > 3 maanden geleden geplaatst zonder extra\", \" \", mdx(Popover, {\n    content: mdx(Risicofactoren, {\n      mdxType: \"Risicofactoren\"\n    }),\n    title: \"Extra risicofactoren hartklepprothese\",\n    mdxType: \"Popover\"\n  }, mdx(\"a\", {\n    href: \"#\"\n  }, \"risicofactor\"))), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Bioklep > 3 maanden geleden geplaatst\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Recidiverend herseninfarct/TIA zonder additionele hoog risicofactor (atriumfibrilleren, symptomatische, signifcante ACI stenose, antifosfolipidensyndroom)\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"Eenmalig TIA/herseninfarct\"), mdx(ListItem, {\n    mdxType: \"ListItem\"\n  }, \"> 3 maanden na eerste of recidief VTE en geen recidief onder antistolling\")));\n}\n;\nMDXContent.isMDXComponent = true;","tableOfContents":{"items":[{"url":"#hoog-risico","title":"Hoog risico","items":[{"url":"#klinische-status-hoog-risico","title":"Klinische status hoog risico"}]},{"url":"#laag-risico","title":"Laag risico","items":[{"url":"#klinische-status-laag-risico","title":"Klinische status laag risico"}]}]},"parent":{"relativePath":"periprocedureel-beleid/overzicht-trombo-embolie-risico.mdx"},"frontmatter":{"parent":"Periprocedureel Beleid","date":"26-07-2023","nextUrl":"/periprocedureel-beleid/overzicht-periprocedureel-bloedingsrisico","nextText":"Overzicht periprocedureel bloedingsrisico","previousUrl":"/periprocedureel-beleid/algemene-informatie","previousText":"Periprocedureel beleid"}},"allMdx":{"edges":[{"node":{"fields":{"slug":"/afbakening","title":"Afbakening"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica","title":"Bloedingen onder antitrombotica"}}},{"node":{"fields":{"slug":"/colofon","title":"Colofon"}}},{"node":{"fields":{"slug":"/contact","title":"Contact"}}},{"node":{"fields":{"slug":"/inleiding","title":"Inleiding"}}},{"node":{"fields":{"slug":"/colofon/afkortingenlijst","title":"Afkortingenlijst"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/gezamenlijke-besluitvorming","title":"Gezamenlijke besluitvorming"}}},{"node":{"fields":{"slug":"/colofon/verantwoording","title":"Verantwoording"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/informatievoorziening","title":"Informatievoorziening"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/therapietrouw","title":"Therapietrouw"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/veelgestelde-vragen-over-doacs","title":"Veelgestelde vragen over DOACs"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/overzicht-periprocedureel-bloedingsrisico","title":"Overzicht periprocedureel bloedingsrisico"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/overzicht-trombo-embolie-risico","title":"Overzicht trombo-embolie risico"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-factor-xa-remmers-rivaroxaban-apixaban-edoxaban","title":"Beslisboom DOAC - factor Xa-remmers, Rivaroxaban, Apixaban, Edoxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-beleid-bij-bloedingen-voor-de-huisarts","title":"Beslisboom Beleid bij bloedingen voor de huisarts"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-doac","title":"Beslisboom DOAC"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-apixaban","title":"Beslisboom Apixaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/bloeding-onder-lmwh-ongefractioneerde-heparine","title":"Bloeding onder LMWH/ ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-rivaroxaban","title":"Beslisboom Rivaroxaban"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-prasugrel-clopidogrel-ticagrelor","title":"Beslisboom DAPT ASA en prasugrel, clopidogrel, ticagrelor"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-dipyridamol","title":"Beslisboom DAPT ASA en dipyridamol"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-monotherapie-clopidogrel-of-asa","title":"Beslisboom monotherapie Clopidogrel of ASA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/minimale-duur-onderbreken-en-herstarten-dapt","title":"Minimale duur onderbreken en herstarten DAPT"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/doac/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/doac/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/lmwh/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/tar/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/tar/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-edoxaban","title":"Beslisboom Edoxaban"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/vka/follow-up-controles","title":"Follow-up controles"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/vka/overzicht","title":"Overzicht"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-dabigatran/schematisch","title":"Beslisboom DOAC- dabigatran"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-tar/schematisch","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-doac/schematisch","title":"Beslisboom DOAC"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-apixaban/schematisch","title":"Beslisboom Apixaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-tar/schematisch","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-dabigatran/schematisch","title":"Beslisboom Dabigatran"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-rivaroxaban/schematisch","title":"Beslisboom Rivaroxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-factor-xa-remmers-rivaroxaban-apixaban-edoxaban/schematisch","title":"Beslisboom DOAC - factor Xa-remmers, Rivaroxaban, Apixaban, Edoxaban"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-edoxaban/schematisch","title":"Beslisboom Edoxaban"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-beleid-bij-bloedingen-voor-de-huisarts/schematisch","title":"Beslisboom Beleid bij bloedingen voor de huisarts"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-dipyridamol/schematisch","title":"Beslisboom DAPT ASA en dipyridamol"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-monotherapie-clopidogrel-of-asa/schematisch","title":"Beslisboom monotherapie Clopidogrel of ASA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/beslisboom-vka/schematisch","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/beslisboom-dapt-asa-en-prasugrel-clopidogrel-ticagrelor/schematisch","title":"Beslisboom DAPT ASA en prasugrel, clopidogrel, ticagrelor"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/tar/dual-antiplatelet-therapy-dapt-behandeling","title":"Dual Antiplatelet Therapy (DAPT) behandeling"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/aanbevelingen-overbrugging-en-herstarten-vka","title":"Aanbevelingen overbrugging en herstarten VKA"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/lmwh/dosering-lmwh-bij-verminderde-nierfunctie","title":"Dosering LMWH bij verminderde nierfunctie"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/hoog-complexe-antistolling","title":"Hoog complexe antistolling"}}},{"node":{"fields":{"slug":"/voorschrijven-en-follow-up/laag-complexe-antistolling","title":"Laag complexe antistolling"}}},{"node":{"fields":{"slug":"/literatuur","title":"Literatuur"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-doac-dabigatran","title":"Beslisboom DOAC - dabigatran"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/vka/beslisboom-vka","title":"Beslisboom VKA"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/extra-opmerkingen-tandheelkundige-ingrepen","title":"Extra opmerkingen tandheelkundige ingrepen"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/doac/beslisboom-dabigatran","title":"Beslisboom Dabigatran"}}},{"node":{"fields":{"slug":"/communicatie-met-patienten/veelgestelde-vragen-over-vka","title":"Veelgestelde vragen over VKA"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine/schematisch","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-tar","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/algemene-informatie","title":"Algemene informatie"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine/schematisch","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/niet-ernstige-bloedingen/beslisboom-tar","title":"Beslisboom TAR"}}},{"node":{"fields":{"slug":"/changelog","title":"Changelog"}}},{"node":{"fields":{"slug":"/bloedingen-onder-antitrombotica/ernstige-bloedingen/beslisboom-lmwh-ongefractioneerde-heparine","title":"Beslisboom LMWH/ongefractioneerde heparine"}}},{"node":{"fields":{"slug":"/","title":"Welkom!"}}},{"node":{"fields":{"slug":"/periprocedureel-beleid/extra-opmerkingen-endoscopische-ingrepen","title":"Extra opmerkingen endoscopische ingrepen"}}}]}},"pageContext":{"id":"664917d9-6333-5061-b704-198f1e1f97f6"}},
    "staticQueryHashes": ["1620603387","2744294623","3578633366","3706406642","4066733661"]}